HemoCue AB Sustainability Profile
HemoCue AB, a leading innovator in point-of-care testing, is headquartered in Sweden (SE) and operates globally, with a strong presence in Europe, North America, and Asia. Founded in 1982, the company has established itself as a pioneer in the development of diagnostic solutions, particularly in the fields of haemoglobin and glucose testing. HemoCue's core products, including the HemoCue® Hb 201+ and HemoCue® Glucose 201+, are renowned for their accuracy, ease of use, and rapid results, making them essential tools in clinical settings. The company’s commitment to quality and innovation has positioned it as a trusted partner in healthcare, contributing to improved patient outcomes worldwide. With numerous accolades and a robust market presence, HemoCue continues to lead the way in advancing diagnostic technology.
DitchCarbon Score
How does HemoCue AB's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Machinery and Equipment industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HemoCue AB's score of 60 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HemoCue AB, headquartered in Sweden (SE), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Danaher Corporation, which influences its climate commitments and reporting practices. HemoCue AB's climate initiatives and reduction targets are cascaded from Danaher Corporation. This includes adherence to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are integral to Danaher's sustainability strategy. However, specific reduction targets or achievements for HemoCue AB have not been disclosed. As part of its corporate family, HemoCue AB aligns with Danaher Corporation's broader climate commitments, which focus on reducing greenhouse gas emissions across all scopes. The absence of specific emissions data highlights the need for ongoing transparency and accountability in climate reporting within the organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 138,341,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 219,166,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
How Carbon Intensive is HemoCue AB's Industry?
How Carbon Intensive is HemoCue AB's Location?
HemoCue AB's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
HemoCue AB has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
